Men genetically predisposed to the most common form of hair loss face an additional 7 percent risk of shedding hair when using GLP-1 receptor agonists like Ozempic, Wegovy, and Zepbound, according to a study published on September 3 in the Journal of Investigative Dermatology. Researchers at NYU Langone Health examined the genetic mechanisms linking popular diabetes and obesity medications to androgenetic alopecia, finding that overlapping genetic risks may explain a side effect long reported by patients but until now unproven scientifically.
NYU Langone Health Researchers Examine GLP1R Gene Activity
To uncover the biological connection, a research team led by Dr. Lynn Petukhova examined the GLP1R gene, which naturally controls glucagon-like peptide-1 receptor proteins in the body. Rather than tracking direct drug administration, the investigators used gene activity as a proxy for drug exposure. Individuals with higher GLP1R activity naturally possess more receptor proteins, mimicking the physiological state of someone taking a GLP-1 agonist.
The investigators cross-referenced these genetic patterns with data from large public repositories, including information from 31,684 participants in the eQTLGen database and 205,327 individuals from the Complex Traits Genetics group database, both consisting mostly of White adults. By analyzing the incidence of androgenetic alopecia—the inherited pattern of hair thinning affecting the front and top of the scalp—among men with varying levels of GLP1R activity, the team isolated the 7 percent risk increase.
Did you know? An estimated 12 percent of Americans have used GLP-1 medications solely for weight loss, including one-fifth of women aged 50 to 64, according to survey data. Prescriptions have more than tripled since the Food and Drug Administration first approved Ozempic in 2020.
Ruling Out Hypertension and Insulin Resistance
To ensure the findings were robust, the NYU Langone team tested whether other health conditions accounted for the association. High blood pressure restricts blood flow to the scalp and damages hair follicles, making hypertension a major confounding variable. Even after adjusting the statistical analysis to account for hypertension, the 7 percent elevated risk of hair loss persisted.
The researchers also investigated whether insulin resistance—a core driver of type 2 diabetes—or reduced testosterone levels explained the overlap. Neither factor altered the results. According to Dr. Petukhova, an assistant professor in the Ronald O. Perelman Department of Dermatology and the Department of Population Health at NYU Grossman School of Medicine, the data confirm a shared underlying biological connection between GLP-1 pathway activity and male-pattern baldness.
Comparing Study Findings With Prior Diabetes Drug Research
While the NYU Langone study focused on genetic predisposition in men, other recent investigations have examined actual hair loss diagnoses among broader patient populations. Research published in The BMJ by a team at the University of Pennsylvania medical school found that patients with type 2 diabetes taking GLP-1 medications faced hair loss risks 37 percent and 68 percent higher than users of older diabetes treatments such as SGLT-2 and DPP-4 inhibitors, respectively.
However, actual clinical diagnosis rates remain low, tracking between three and nine cases per 1,000 people annually. Medical researchers have frequently attributed these shedding events to telogen effluvium, a temporary condition triggered by rapid weight loss that pushes growing hair follicles prematurely into a resting phase. Patients often report that hair regrowth resumes several months after their weight stabilizes.
Key Studies on GLP-1 Medications and Hair Loss
- NYU Langone Study (Journal of Investigative Dermatology): Found a 7 percent increased risk of androgenetic alopecia in men with genetic variants tied to higher GLP1R activity.
- University of Pennsylvania Study (The BMJ): Reported that type 2 diabetes patients on GLP-1 drugs had 37% to 68% higher relative risks of hair loss compared to those taking SGLT-2 or DPP-4 inhibitors.
Future Screening and Preventive Treatments
The latest genetic insights could change how doctors prescribe weight-loss and diabetes medications. Dr. Petukhova noted that if future clinical trials succeed, physicians could screen patients for genetic vulnerability before prescribing drugs like Wegovy or Zepbound.
“We could also envision these findings leading to some GLP-1 users being prescribed combination treatments to prevent hair loss, such as minoxidil or some other drug,” Dr. Petukhova said. Additional research is required to map the exact cellular mechanisms by which GLP-1 receptor activity interferes with follicle growth, as well as to determine whether the genetic link applies equally to women.
Frequently Asked Questions
Do GLP-1 drugs like Ozempic cause permanent hair loss?
Most patients experiencing shedding due to rapid weight loss report that hair begins growing back several months after their weight stabilizes.
Does this hair loss risk affect women?
Because male hair loss has been studied far more extensively than hair loss in women, the researchers were only able to investigate a possible causal connection in men.
Can genetic screening prevent this side effect?
Researchers suggest that future medical protocols might screen patients for genetic risk factors and prescribe preventive treatments like minoxidil alongside GLP-1 medications.
Stay Informed on Health Research
Subscribe to our newsletter for the latest updates on medical studies, drug safety, and wellness breakthroughs.
Worth a look